ClinicalTrials.gg

Program

zodasiran

Also written as “ARO-ANG3”, “Zodasiran” and “zodasiran Injection”.

Its studies are mostly in Homozygous Familial Hypercholesterolemia · Dyslipidemias, led by Arrowhead Pharmaceuticals.

Furthest: phase 3, since Jun 17, 20254 company-led studies, 2 open or runningNext primary completion: Aug 20, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Arrowhead Pharmaceuticals42 open or runningphase 3since Jun 17, 2025Nov 16, 2018Aug 20, 2027phase 3 · NCT07037771

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 16, 2018First study: phase 1 study in DyslipidemiasFirst studyNCT03747224 · 93 enrolled · Australia, New Zealand
  2. Apr 2, 2021Phase 2 study in Mixed DyslipidemiaNCT04832971 · 204 enrolled · United States, Australia, Canada and more
  3. Jun 17, 2025Phase 3 study in Homozygous Familial HypercholesterolemiaNCT07037771 · 70 enrolled · United States, Australia, Austria and more
  4. Mar 11, 2026Phase 3 study in Homozygous Familial HypercholesterolemiaNCT07473843 · 10 planned · United States, Denmark, Poland

Ahead

  1. Aug 20, 2027Primary completion: phase 3 study in Homozygous Familial HypercholesterolemiaNCT07037771
  2. Jul 2028Primary completion: phase 3 study in Homozygous Familial HypercholesterolemiaNCT07473843

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07473843Homozygous Familial Hypercholesterolemia · United States, Denmark, Poland3RecruitingJul 202810
NCT07037771Homozygous Familial Hypercholesterolemia · United States, Australia, Austria and more3Active, not recruitingAug 20, 202770
NCT04832971Mixed Dyslipidemia · United States, Australia, Canada and more2CompletedAug 30, 2022204
NCT03747224Dyslipidemias · Australia, New Zealand1CompletedMay 17, 202193

How it is read

Names in the registry

  • “ARO-ANG3”, 2 entries
  • “Zodasiran”, 1 entry
  • “zodasiran Injection”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.